

3 A unified approach to NGS-based oncology companion diagnostic development

Jim Godsey

Vice President, Clinical NGS and Oncology,
Thermo Fisher Scientific, Inc.

There is increasing interest from pharmaceutical and regulatory communities, alike, in the development of a multi-marker companion diagnostic product to support the increasing number of targeted therapies that address small cancer sub-populations. Traditionally, pharmaceutical and diagnostic development partners have designed individual companion diagnostic products for each therapeutic candidate, however, this has proven costly, time-consuming, and is increasingly impractical in the marketplace as the number of targeted therapies and individual companion tests grow. The use of an NGS-based approach to address these challenges will be described using Ion Torrent technology and Oncomine reagents.